three years of 503A threads, summarised so you do not have to read them
three years of 503A threads, summarised so you do not have to read them — a position I have arrived at slowly and would like tested.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
shortage status changes and the whole arrangement changes with it
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
potency testing on the finished preparation is the thing to ask for
On concentration, which is where I see people actually get hurt.
prior_auth_pain is right about the concentration trap. It breaks arithmetic that has been reliable for months.
the API source is the question nobody asks and everybody should
compounded is not generic, there is no equivalence claim
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which ch
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
503A or 503B — do you know which?
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
- 1On concentration, which is where I see people actually get hurt. A…9 comments in this branch · started by u/prior_auth_pain